Citation Impact
Citing Papers
Probing mucin-type O-linked glycosylation in living animals
2006 StandoutNobel
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
A metabolic labeling approach toward proteomic analysis of mucin-type O-linked glycosylation
2003 StandoutNobel
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Estrogen Dendrimer Conjugates that Preferentially Activate Extranuclear, Nongenomic Versus Genomic Pathways of Estrogen Action
2005
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.
2001
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
1996
Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
2003
Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer
2003
ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
2003
Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
2016
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
1995
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
2009
Humanization of an anti-p185HER2 antibody for human cancer therapy.
1992
Antitumor activity of HER-2 inhibitors
2004
Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer
2002
HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer
2000
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
2002
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
1999
Biologic and therapeutic role of HER2 in cancer
2003
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
2001
Identification of Heregulin, a Specific Activator of p185 erbB2
1992 Science
Bivalence of EGF-like ligands drives the ErbB signaling network
1997
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
2001
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells.
1991
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.
2001
EGFR Antagonists in Cancer Treatment
2008 Standout
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor
2000
Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry
2003
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
Epidermal growth factor-related peptides and their receptors in human malignancies
1995 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor
1991
Antibody-targeted radiation cancer therapy
2004
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
1998
Genetic instabilities in human cancers
1998 StandoutNature
Cancer immunotherapy: breaking the barriers to harvest the crop
2004 StandoutNobel
When Checkpoints Fail
1997 StandoutNobel
Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance
2010
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
The origin of pattern and polarity in the Drosophila embryo
1992 StandoutNobel
Lymphangiogenesis in development and human disease
2005 StandoutNature
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons
1996 StandoutNature
ErbBs in lung cancer
2008
A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm
2002 Nature
Targeting the function of the HER2 oncogene in human cancer therapeutics
2007
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
The molecular biology of breast cancer
1991
Signaling antibodies in cancer therapy
1999
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
1996 Standout
Phosphatidylinositol 4-Kinases and the Role of Polyphosphoinositides in Cellular Regulation
1992
Deoxyribonucleoside triphosphate levels: A critical factor in the maintenance of genetic stability
1994
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer
2003
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
1998
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
A Novel Family of Phosphatidylinositol 4-Kinases Conserved from Yeast to Humans
2001 StandoutNobel
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
2005
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
2007 StandoutNobel
AKT/PKB Signaling: Navigating the Network
2017 Standout
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
2002
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Recent insights into platinum drug resistance in cancer
1998
Mammalian deoxyribonucleoside kinases
1995
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Cell Signaling by Receptor Tyrosine Kinases
2000 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)*
2001
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.
1992
Fulvestrant (Faslodex®)—How to Make a Good Drug Better
2007
Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics
2002 StandoutScience
Type 1 growth factor receptors: an overview of recent developments
1995
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
The Cation−π Interaction
1997 Standout
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer
2002
Drug Discovery: A Historical Perspective
2000 StandoutScience
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
1990 StandoutScience
"Diabodies": small bivalent and bispecific antibody fragments.
1993 StandoutNobel
Growth Factors and Cancer
1991 StandoutScience
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
2000
Compact Biocompatible Quantum Dots Functionalized for Cellular Imaging
2008 StandoutNobel
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
1995 StandoutScience
Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system.
1992 StandoutNobel
Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule
2005
Chemical Glycoproteomics
2016 StandoutNobel
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Mass Spectrometry and Protein Analysis
2006 StandoutScience
Works of Jay Sarup being referenced
Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
1991
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
1992
The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.
1990
p185HER2 signal transduction in breast cancer cells
1991
Inhibition of T Lymphocyte Actnation by a Novel p56lckTyrosine Kinase Inhibitor
1995
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
1991
Regulation of purine deoxynucleoside phosphorylation by deoxycytidine kinase from human leukemic blast cells
1989
Approach to the discovery of novel, selective inhibitors of p56lck tyrosine kinase: Identification of non‐hydroxylated chromones as p56lck inhibitors
1995
Identification of purine deoxyribonucleoside kinases from human leukemia cells: substrate activation by purine and pyrimidine deoxyribonucleosides
1987
Direct Interaction of a Ligand for the erb B2 Oncogene Product with the EGF Receptor and p185 erb B2
1990 Science